 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12345678910111213...2223» |
- || Phase classification, Enrollment change: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Aug 8, 2023
P1, N=25, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
Phase classification: P2 --> P1 | N=131 --> 25
- | Halaven (eribulin mesylate) / Eisai
New trial, Metastases: A Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01). (clinicaltrials.gov) - Jul 20, 2023
P=N/A, N=120, Active, not recruiting, Sponsor: Fujian Cancer Hospital
- | everolimus / Generic mfg.
New P3 trial, Metastases: BCTOP-T-M03: Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype (clinicaltrials.gov) - Jul 20, 2023
P3, N=203, Not yet recruiting, Sponsor: Fudan University
- |||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Enrollment open: SHR-A1811-III-306: SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (clinicaltrials.gov) - Jul 20, 2023
P3, N=530, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Phase classification: P2 --> P1 | N=131 --> 25 Not yet recruiting --> Recruiting
- |||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
New trial: DESTINY Breast Respond HER2-low Europe (clinicaltrials.gov) - Jul 14, 2023
P=N/A, N=1350, Not yet recruiting, Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC (clinicaltrials.gov) - Jul 14, 2023
P2, N=78, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Jul 7, 2023
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Sep 2023
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
New P3 trial: Study Evaluating SHEN26 Capsule in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - Jun 18, 2023
P3, N=1200, Recruiting, Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
- | Biomarker, Enrollment open, Circulating tumor DNA: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov) - Jun 18, 2023
P2, N=500, Recruiting, Sponsor: University of Miami
Trial completion date: Dec 2023 --> Sep 2023 Not yet recruiting --> Recruiting
- | Xpovio (selinexor) / Karyopharm
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Jun 18, 2023
P1, N=221, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024
- | SHEN26 / Shenzhen Kexing Pharma, Shenzhen Antaiwei Biopharm
Trial completion: Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 (clinicaltrials.gov) - Jun 18, 2023
P2, N=91, Completed, Sponsor: Shenzhen Kexing Pharmaceutical Co., Ltd.
Recruiting --> Active, not recruiting | N=390 --> 221 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Dec 2024 Recruiting --> Completed
- ||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] (clinicaltrials.gov) - Jun 15, 2023
P3, N=557, Active, not recruiting, Sponsor: Daiichi Sankyo, Inc.
Recruiting --> Completed Trial completion date: Mar 2023 --> Mar 2024
- ||| Enrollment change, Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 9, 2023
P1/2, N=242, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Mar 2023 --> Mar 2024 N=133 --> 242 | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026
- | Halaven (eribulin mesylate) / Eisai, Tecentriq (atezolizumab) / Roche
Enrollment closed, IO biomarker: Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (clinicaltrials.gov) - Jun 5, 2023
P2, N=72, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=133 --> 242 | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: May 2024 --> May 2026 Recruiting --> Active, not recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial suspension: SWOG S1937: Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (clinicaltrials.gov) - Jun 1, 2023
P3, N=465, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Suspended
- || Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment open, IO biomarker: EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (clinicaltrials.gov) - Jun 1, 2023
P2, N=30, Recruiting, Sponsor: Australia New Zealand Gynaecological Oncology Group
Recruiting --> Suspended Not yet recruiting --> Recruiting
- || izorlisib (MEN1611) / Menarini, Halaven (eribulin mesylate) / Eisai
Enrollment open, Monotherapy: SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (clinicaltrials.gov) - May 30, 2023
P2, N=28, Recruiting, Sponsor: MedSIR
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: Efficacy of Tislelizumab administered in combination with eribulin and anlotinib for patients (pts) with advanced adult soft tissue sarcoma (TEASTS) (EUDRACT) - May 25, 2023
P2, N=26, Recruiting, Sponsor: Zhongshan Hospital, Fudan University
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date, Metastases: HERMIONE-10: Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer (clinicaltrials.gov) - May 25, 2023
P=N/A, N=200, Recruiting, Sponsor: University of Milano Bicocca
Not yet recruiting --> Recruiting Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023
- | Halaven (eribulin mesylate) / Eisai, grapiprant (RQ-00000007) / AskAt, Ikena Oncology, Maruishi Pharma
Enrollment closed, Metastases: Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - May 25, 2023
P1/2, N=25, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2023 --> Dec 2023 | Trial primary completion date: Mar 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- ||||||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion, Trial completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - May 25, 2023
P3, N=436, Completed, Sponsor: Byondis B.V.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022
- | Enrollment change, Trial withdrawal: Implantable Microdevice for TNBC - Pilot Study (clinicaltrials.gov) - May 18, 2023
P1, N=0, Withdrawn, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022 N=24 --> 0 | Not yet recruiting --> Withdrawn
- || Halaven (eribulin mesylate) / Eisai
Enrollment closed: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery (clinicaltrials.gov) - May 17, 2023
P1b, N=15, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=24 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Trial completion date, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - May 12, 2023
P=N/A, N=35, Recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Active, not recruiting Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
- | Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - May 11, 2023
P2, N=35, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Jun 2023 --> Jun 2024 Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024
- | Halaven (eribulin mesylate) / Eisai
New P2 trial: ERICA: Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients (clinicaltrials.gov) - Apr 27, 2023
P2, N=122, Active, not recruiting, Sponsor: Consorzio Oncotech
- | Biomarker, New P2 trial, Circulating tumor DNA: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov) - Apr 24, 2023
P2, N=500, Not yet recruiting, Sponsor: University of Miami
- |||| GI-102 / GI Innovation
New P1/2 trial: A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) (clinicaltrials.gov) - Apr 24, 2023
P1/2, N=92, Recruiting, Sponsor: GI Innovation, Inc.
- ||| paclitaxel trevatide (ANG1005) / Angiochem
Trial primary completion date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Apr 20, 2023
P3, N=150, Not yet recruiting, Sponsor: Angiochem Inc
Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Dec 2024 Trial primary completion date: Mar 2024 --> Dec 2024
- || Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: AIRE: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (clinicaltrials.gov) - Apr 18, 2023
P4, N=82, Recruiting, Sponsor: Institut fuer Frauengesundheit
Trial primary completion date: Mar 2024 --> Dec 2024 Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Jul 2023
- |||||||||| trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P3 trial: SHR-A1811-III-306: SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial (clinicaltrials.gov) - Apr 14, 2023
P3, N=528, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, IO biomarker: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Apr 12, 2023
P2, N=46, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Jul 2023 Trial completion date: Dec 2022 --> Aug 2023
- | izorlisib (MEN1611) / Menarini, Halaven (eribulin mesylate) / Eisai
New P2 trial, Monotherapy: SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (clinicaltrials.gov) - Apr 12, 2023
P2, N=28, Not yet recruiting, Sponsor: MedSIR
- | Avastin (bevacizumab) / Roche, Halaven (eribulin mesylate) / Eisai
New P3 trial, Metastases: BCTOP-T-M01: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Apr 10, 2023
P3, N=192, Recruiting, Sponsor: Fudan University
- | Epidaza (chidamide) / Chipscreen
Enrollment open, Trial completion date, Trial primary completion date: Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure (clinicaltrials.gov) - Apr 6, 2023
P1/2, N=87, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Dec 2022 --> Aug 2023 Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> Nov 2025 | Trial primary completion date: Jul 2023 --> May 2025
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open: BCTOP-T-M02: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (clinicaltrials.gov) - Mar 28, 2023
P3, N=223, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting | Trial completion date: Jul 2024 --> Nov 2025 | Trial primary completion date: Jul 2023 --> May 2025 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai
Trial completion date: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Mar 22, 2023
P2, N=22, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Recruiting Trial completion date: Feb 2023 --> Dec 2023
- | Halaven (eribulin mesylate) / Eisai
Trial completion date, Metastases: Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors (clinicaltrials.gov) - Mar 21, 2023
P1, N=8, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Feb 2023 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2023
- | balixafortide (POL 6326) / Spexis, Halaven (eribulin mesylate) / Eisai
Enrollment change, Trial withdrawal: POLTER: POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Mar 20, 2023
P1/2, N=0, Withdrawn, Sponsor: MedSIR
Trial completion date: Dec 2022 --> Dec 2023 N=168 --> 0 | Not yet recruiting --> Withdrawn
- | New P1 trial: Implantable Microdevice for TNBC - Pilot Study (clinicaltrials.gov) - Mar 20, 2023
P1, N=24, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | Halaven (eribulin mesylate) / Eisai
Enrollment closed: Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) (clinicaltrials.gov) - Mar 20, 2023
P2, N=13, Active, not recruiting, Sponsor: Massachusetts General Hospital
N=168 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P3 trial: BCTOP-T-M02: Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (clinicaltrials.gov) - Mar 8, 2023
P3, N=223, Not yet recruiting, Sponsor: Fudan University
- |||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Trial primary completion date: EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov) - Mar 3, 2023
P3, N=331, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2023 --> Mar 2024
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion date, Monotherapy, Metastases: OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov) - Feb 28, 2023
P3, N=302, Active, not recruiting, Sponsor: AstraZeneca
Trial primary completion date: Mar 2023 --> Mar 2024 Trial completion date: Dec 2022 --> Dec 2023
- ||| Halaven (eribulin mesylate) / Eisai
Trial termination: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 13, 2023
P1, N=10, Terminated, Sponsor: Athenex, Inc.
Trial completion date: Dec 2022 --> Dec 2023 Completed --> Terminated; Sponsor Decision
- ||| Enrollment change: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 9, 2023
P1/2, N=133, Active, not recruiting, Sponsor: Hoffmann-La Roche
Completed --> Terminated; Sponsor Decision N=280 --> 133
- || Trodelvy (sacituzumab govitecan-hziy) / Gilead, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Scalp Cooling in MBC (clinicaltrials.gov) - Feb 8, 2023
P2, N=120, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=280 --> 133 Trial primary completion date: Jun 2023 --> Jun 2024
- |||| BB-1705 / BlissBio
Enrollment open, Metastases: A First-in-human of Multiplle Doses of BB-1705 in Subjects With Locally Advanced/Metastatic Solid Tumors (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=288, Recruiting, Sponsor: Bliss Biopharmaceutical (Hangzhou) Co., Ltd
Trial primary completion date: Jun 2023 --> Jun 2024 Not yet recruiting --> Recruiting
- | Halaven (eribulin mesylate) / Eisai, Aliqopa (copanlisib) / Bayer
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=106, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Suspended --> Recruiting | N=18 --> 106 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Trial completion date: Evaluate Eribulin ORA in Subjects With Solid Tumors (clinicaltrials.gov) - Feb 8, 2023
P1, N=10, Completed, Sponsor: Athenex, Inc.
Suspended --> Recruiting | N=18 --> 106 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Completed | N=50 --> 10 | Trial completion date: Jul 2022 --> Mar 2022